UPDATE: Ascendiant Capital Markets Reiterates On Repros Therapeutics Following Positive Topline Results
August 29, 2014 at 07:53 AM EDT
In a report published Friday, Ascendiant Capital Markets analyst Keay Nakae reiterated a Buy rating on Repros Therapeutics (NASDAQ: ...